Taysha Gene (TSHA) Plunges Over 9% Intraday—Volatility Spikes Amid Technical Divergence and Bearish Setup

Summary
• Taysha Gene’s stock has plummeted to $4.118, a 9.3% drop from its previous close of $4.54.
• Intraday volatility has pushed the stock to a low of $4.075, just above its 52-week low of $1.05.
• Options market activity shows a sharp increase in implied volatility, particularly in the April 2026 expiries.

The market is reacting with urgency to a sharp intraday selloff in Taysha Gene. The stock is trading well below both its 30-day and 200-day moving averages, raising concerns about near-term momentum and technical support. As traders assess the options market, the signs are pointing to a possible continuation of the bearish move in the short term.

Bearish Momentum Fueled by Technical Divergence and Short-Selling Pressure
Taysha Gene's sharp decline is driven by deteriorating technical momentum and growing short-term bearish signals. The RSI has dipped into the 50 range, suggesting a weakening trend from its short-term overbought levels. The MACD is also negative and below its signal line, signaling ongoing downward pressure. Bollinger Bands confirm the move as the price is trading near the lower band, indicating a strong pull toward the downside. With the stock trading below key moving averages, particularly the 200-day line at $3.97, it’s reinforcing a bearish bias as the market loses near-term conviction in its value proposition.

Biotech Sector Holds Steady—Taysha Gene Drags as Merck Gains 0.2%
The biotechnology sector remains relatively flat with Merck (MRK) rising 0.2%, signaling broad resilience amid Taysha Gene’s selloff. Taysha’s sharp drop is stock-specific and not indicative of sector-wide sentiment. Investors are likely rotating out of smaller-cap names like TSHA in favor of more established players like MRK, which continues to offer stability and momentum. This divergence highlights the growing risk aversion in the sector, especially for speculative biotech plays.

Capitalizing on the Downside: Strategic Put Options and ETFs for Bearish Exposure
• 200-day average: 3.967 (below current price); RSI: 50.4 (neutral-bearish); MACD: -0.052 (bearish); Bollinger Bands: Lower band at 4.365 (near current price).

The technical picture is bearish, with the stock trading well below both the 30-day and 200-day moving averages. The RSI has fallen into the 50 range, suggesting a loss of momentum. The MACD is negative and below the signal line, reinforcing the downward trend. Bollinger Bands also support the bearish case as the price has collapsed near the lower band. The options market is pricing in high volatility, particularly in the near-term expiries, which aligns with the aggressive selloff observed today. While there’s no leveraged ETF for direct exposure, traders can use the options chain to build a bearish position.

• TSHA20260417P4: Put option, strike price $4, expiration 2026-04-17. Implied volatility: 82.82% (high); Leverage ratio: 14.79% (moderate); Delta: -0.389 (moderate bearishness); Theta: -0.0036 (moderate time decay); Gamma: 0.427 (high sensitivity). This put option is ideal for a bearish stance due to its high gamma and moderate delta, which means it responds well to price drops. The high implied volatility indicates the market expects further movement, and the moderate theta allows for some time before expiration. If the stock falls below $4, this option could deliver strong returns.

• TSHA20260618P4: Put option, strike price $4, expiration 2026-06-18. Implied volatility: 100.84% (very high); Leverage ratio: 5.91% (moderate); Delta: -0.368 (moderate bearishness); Theta: -0.0033 (moderate time decay); Gamma: 0.185 (moderate sensitivity). This longer-dated put offers more time for the bearish move to play out, with higher implied volatility and strong gamma. It’s suitable for a more strategic bearish approach with a longer time horizon. Given the projected 5% downside to $3.912, this put would yield a payoff of approximately $0.088 (max gain if stock hits $0).

The key level to watch is the 200-day moving average at $3.967. A breakdown below this could trigger deeper bearish momentum. Aggressive bearish traders may consider the TSHA20260417P4 to play the near-term drop, while more strategic players might prefer the TSHA20260618P4 for a longer bearish setup. For now, if $4.00 breaks, TSHA20260417P4 offers high potential return in a short window.

Backtest Taysha Gene Stock Performance
The performance of TSHA after a -9% intraday plunge from 2022 to now has shown mixed results in the backtest. While the 3-day win rate is moderate at 48.77%, the 10-day win rate is slightly higher at 51.98%, and the 30-day win rate is 48.20%, indicating a higher probability of positive returns in the short term. The maximum return during the backtest period was 8.55%, which occurred on day 59, suggesting that while there is potential for gains, the performance is not consistently strong.

Aggressive Bearish Move—Now Is the Time to Secure a Short Position
The sharp decline in Taysha Gene is not a short-term blip—it’s a technical breakdown with clear bearish momentum. With the stock well below its key moving averages and options volatility spiking, the market is pricing in a continuation of the downtrend. Investors should closely monitor the $4.00 level as a key support, and any break below that would likely trigger further selling. The biotech sector is holding steady with Merck rising 0.2%, highlighting that the selloff in TSHA is stock-specific. Traders are advised to consider bearish options like TSHA20260417P4 for high gamma exposure and leverage. Watch for a breakdown below $3.967 and consider adding a short bias before volatility spikes further.